HT-001 Topical

Phase 2

ICON PLC (ICLR)

00%

What is LOA?

Phase 2

Development Phase

Upcoming Catalysts

Historical Events

Regulatory Approvals

Upcoming Catalysts

What are catalysts?

Dec '26

ICLRPhase 2$12.8B

HT-001 Topical Phase 2 Est. Readout

HT-001 Topical• Acneiform Eruption Due to Chemical152

Dec 2026~Confirmed

CT.gov

00%

Competitive Landscape

0 competitors in Acneiform Eruption Due to Chemical

View Full Landscape

Drug Information

Target Indication

Acneiform Eruption Due to Chemical

Clinical Trial

NCT05639933

Last updated: 10/16/2026

Patent & Exclusivity

No patent data available. Pre-approval drugs may not have Orange Book listings.

Source: FDA Orange Book

Drug Science

Mechanism of action & safety profile

Developer

ICLR

ICON PLC

Services-Commercial Physical & Biological Research•North America•NASDAQ

Related Pipeline

IBI-10090Phase 3

Inflammation

ClascoteronePhase 3

Alopecia, Androgenetic

padeliporfin VTPPhase 3

Transitional Cell Cancer of Renal Pelvis and Ureter

IgPro20 (low dose)Phase 3

Chronic Inflammatory Demyelinating Polyneuropathy

NecitumumabPhase 3

Non Small Cell Lung Cancer

View full pipeline

Get Catalyst Alerts

Receive weekly digests of upcoming catalysts